SURVIVAL OUTCOMES IN EARLY GLOTTIC CARCINOMA; A SINGLE INSTITUTION EXPERIENCE
Abstract
Purpose: Laryngeal cancers are amongst the most common cancers affecting head and neck region. In this study, we analyse the overall survival (OS) following hypofractionated radiotherapy (RT) in early stage glottic carcinoma treated at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore.
Methods: Between October 2003 and June 2009, 87 patients with early stage glottic carcinoma were treated with hypofractionated RT. All patients were included in the study. The ratio of male: female is 94%:6%. Mean age was 62 years (range 31–83 years). 66% of the patients were smokers. AJCC stage was T1a in 76%, T1b 20% and T2 in 4% of the patients. Histological distribution was; squamous cell carcinoma 97%, verrucous carcinoma 2% and squamous cell spindle variant 1%. Median follow-up time was 59 months (range 4–122 months). RT dose was 55 Gy in 20 fractions over a period of 4 weeks. Median RT treatment time was 28 days (range 23–35 days). Patients that lost to follow-up were contacted through telephone.
Results: The 10-year OS was 83%. Patterns of failure was 7 local and 1 distant while 1 patient had persistent disease. 15 patients were dead at the time of study. Cause of death; 13 patients died due to Ischemic heart disease and 2 due to primary disease.
Conclusion: Hypofractionated RT 55 Gy in 20 fractions seems to achieve good OS while offering potential for optimizing resources usage.
Key words: Glottic carcinoma, hypofractionated, overall survival, radiotherapy
References
Ferlay J, Bray F, Pisani P, et al. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1. Cancer Base No. 5. Lyon: IARC Press; 2001.
Myers EN, Suen JY, Myers JN, Hanna E0. Cancer of the Head and Neck. 4th ed. Philadelphia, PA: Saunders; 2003.
Million RR, Cassisi NJ, Mancuso AA. Larynx. In: Million RR, Cassisi NJ, editors. Management of head and neck cancer, a multidisciplinary approach. 2nd ed. Philadelphia, PA: JB Lippincott; 1994. p. 431-97.
Kaiser TN, Spector GJ. Tumors of the larynx and laryngopharynx. In: Ballanger JJ, editor. Diseases of the Nose, Throat, Ear, Head and Neck. 14th ed. Philadelphia, PA: Lea and Febiger; 1991. p. 682-746.
Mendenhall WM, Amdur RJ, Morris CG, et al. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 2001;19:4029-36.
American Society of Clinical Oncology, Pfister DG, Laurie SA, et al. American society of clinical oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006;24:3693-704.
Mendenhall WM, Parsons JT, Million RR, et al. T1-T2 squamous cell carcinoma of the glottic larynx treated with radiation therapy: Relationship of dose-fractionation factors to local control and complications. Int J Radiat Oncol Biol Phys 1988;15:1267-73.
Mendenhall WM, Parsons JT, Stringer SP, et al. Management of tis, T1, and T2 squamous cell carcinoma of the glottic larynx. Am J Otolaryngol 1994;15:250-7.
Williams MV, James ND, Summers ET, et al. National survey of radiotherapy fractionation practice in 2003. Clin Oncol (R Coll Radiol) 2006;18:3-14.
van der Voet JC, Keus RB, Hart AA, et al. The impact of treatment time and smoking on local control and complications in T1 glottic cancer. Int J Radiat Oncol Biol Phys 1998;42:247-55.
Wang CC. Radiation Therapy for Head and Neck Neoplasms. 2nd ed. Washington DC: Year Book Medical Publishers, Inc.; 1990. p. 228-9.
Warde P, O’Sullivan B, Bristow RG, et al. T1/T2 glottic cancer managed by external beam radiotherapy: The in uence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998;41:347-53.
JamshedA,HussainR,HameedS,etal.Hypopfractionated radiotherapy in the treatment of early glottic carcinoma. 2011. DOI: 10.5005/jp-journals-10001-1069.
Epstein BE, Lee DJ, Kashima H, et al. Stage T1 glottic carcinoma: Results of radiation therapy or laser excision. Radiology 1990;175:567-70.
Cellai E, Chiavacci A, Olmi P. Causes of failure of curative radiation therapy in 205 early glottic cancers. Int J Radiat Oncol Biol Phys 1990;19:1139-42.
Fein DA, Lee WR, Hanlon AL, et al. Do overall treatment time, field size, and treatment energy in uence local control of T1 T2squamous cell carcinomas of the glottic larynx? Int J Radiat Oncol Biol Phys 1996;34:823-31.
MillionRR.Thelarynx.Sotospeak:EverythingIwantedto know about laryngeal cancer I learned in the last 32 years. Int J Radiat Oncol Biol Phys 1992;23:691-704.
SessionsDG,OguraJH,FriedMP.Theanteriorcommissure in glottic carcinoma. Laryngoscope 1975;85:1624-32.
Le QT, Fu KK, Kroll S, et al. In uence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 1997;39:115-26.
Chera BS, Amdur RJ, Morris CG, et al. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with de nitive radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:461-6.
Garden AS, Forster K, Wong PF, et al. Results of radiotherapy for T2N0 glottic carcinoma: Does the “2” stand for twice-daily treatment? Int J Radiat Oncol Biol Phys 2003;55:322-8.
Groome PA, O’Sullivan B, Mackillop WJ, et al. Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: Population- based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys 2006;64:1002-12.
OvergaardJ,AlsnerJ,EriksenJ,etal.Importanceofoverall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck. Rays 2000;25:313-9.
Rudoltz MS, Benammar A, Mohiuddin M. Prognostic factors for local control and survival in T1 squamous cell carcinoma of the glottis. Int J Radiat Oncol Biol Phys 1993;26:767-72.
James ND, Robertson G, Squire CJ, et al. A national audit of radiotherapy in head and neck cancer. Clin Oncol (R Coll Radiol) 2003;15:41-6.
Short S, Krawitz H, Macannn A, et al. T1N0/T2N0 glottic carcinoma: A comparision of two fractionation schedules. Australas Radiol 2006;50:152-157.
KimRY,MarksME,SalterMM.Early-stageglotticcancer: Importance of dose fractionation in radiation therapy. Radiology 1992;182:273 5.
Ricciardelli EJ, Weymuller EA Jr., Koh WJ, et al. Effect of radiation fraction size on local control rates for early glottic carcinoma. A model analysis for in vivo tumor growth and radio response parameters. Arch Otolaryngol Head Neck Surg 1994;120:737-42.
SmallWJr.,MittalBB,BrandWN,etal.Resultsofradiation therapy in early glottic carcinoma: Multivariate analysis of prognostic and radiation therapy variables. Radiology 1992;183:789-94.
Wiernik G, Alcock CJ, Bates TD, et al. Final report on the second British institute of radiology fractionation study: Short versus long overall treatment times for radiotherapy of carcinoma of the laryngo-pharynx. Br J Radiol 1991;64:232-41.
Shimizu R. An evaluation of absorbed doses of high energy electromagnetic radiation in radiotherapy of laryngeal cancer. Nihon Jibiinkoka Gakkai Kaiho 1990;93:796-807.
Akine Y, Tokita N, Ogino T, etal.Radiotherapy of T1 glottic cancer with 6 MeV x rays. Int J Radiat Oncol Biol Phys 1993;26:767-72.
FooteRL,GradoGL,BuskirkSJ,etal.Radiationtherapyfor glottic cancer using 6-MV photons. Cancer 1996;77:381-6.
Steiner W. Results of curative laser microsurgery of laryngeal carcinomas. Am J Otolaryngol 1993;14:116-21.
Spector JG, Sessions DG, Chao KS, et al. Stage I (T1 N0 M0) squamous cell carcinoma of the laryngeal glottis: Therapeutic results and voice preservation. Head Neck 1999;21:707-17.
Ambrosch P. The role of laser micro surgery in the treatment
of laryngeal cancer. Curr Opin Otolaryngol Head Neck Surg
;15:82-8.
Cohen SM, Garrett CG, Dupont WD, et al. Voice-related quality of life in T1 glottic cancer: Irradiation versus endoscopic excision. Ann Otol Rhinol Laryngol 2006;115:581-6.
Dinapoli N, Parrilla C, Galli J, et al. Multidisciplinary approach in the treatment of T1 glottic cancer. The role of patient preference in a homogenous patient population. Strahlenther Onkol 2010;186:607-13.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.
